127 related articles for article (PubMed ID: 34321384)
21. Therapeutic drug monitoring of regorafenib and its metabolite M5 can predict treatment efficacy and the occurrence of skin toxicities.
Taguchi D; Inoue M; Fukuda K; Yoshida T; Shimazu K; Fujita K; Okuyama H; Matsuhashi N; Tsuji A; Yoshida K; Miura M; Shibata H
Int J Clin Oncol; 2020 Apr; 25(4):531-540. PubMed ID: 31807967
[TBL] [Abstract][Full Text] [Related]
22. Risk of hypertension with regorafenib in cancer patients: a systematic review and meta-analysis.
Wang Z; Xu J; Nie W; Huang G; Tang J; Guan X
Eur J Clin Pharmacol; 2014 Feb; 70(2):225-31. PubMed ID: 24150533
[TBL] [Abstract][Full Text] [Related]
23. Regorafenib inhibits growth, angiogenesis, and metastasis in a highly aggressive, orthotopic colon cancer model.
Abou-Elkacem L; Arns S; Brix G; Gremse F; Zopf D; Kiessling F; Lederle W
Mol Cancer Ther; 2013 Jul; 12(7):1322-31. PubMed ID: 23619301
[TBL] [Abstract][Full Text] [Related]
24. Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis.
Belum VR; Wu S; Lacouture ME
Invest New Drugs; 2013 Aug; 31(4):1078-86. PubMed ID: 23700287
[TBL] [Abstract][Full Text] [Related]
25. Regorafenib in gastrointestinal stromal tumors.
Sirohi B; Philip DS; Shrikhande SV
Future Oncol; 2014; 10(9):1581-7. PubMed ID: 25145429
[TBL] [Abstract][Full Text] [Related]
26. Regorafenib: carving a niche in the crowded therapeutic landscape.
Sirohi B; Philip DS; Shrikhande SV
Expert Rev Anticancer Ther; 2013 Apr; 13(4):385-93. PubMed ID: 23560833
[TBL] [Abstract][Full Text] [Related]
27. Regorafenib- associated panniculitis.
Chockalingam R; Aung P; Patel AB
Dermatol Online J; 2016 Jun; 22(6):. PubMed ID: 27617607
[TBL] [Abstract][Full Text] [Related]
28. Involvement of Notch-1 in Resistance to Regorafenib in Colon Cancer Cells.
Mirone G; Perna S; Shukla A; Marfe G
J Cell Physiol; 2016 May; 231(5):1097-105. PubMed ID: 26419617
[TBL] [Abstract][Full Text] [Related]
29. Improving patient outcomes with regorafenib for metastatic colorectal cancer - patient selection, dosing, patient education, prophylaxis, and management of adverse events.
Hofheinz RD; Arnold D; Kubicka S; Prasnikar N; Vogel A
Oncol Res Treat; 2015; 38(6):300-8. PubMed ID: 26045027
[TBL] [Abstract][Full Text] [Related]
30. Regorafenib induced severe toxic hepatitis: characterization and discussion.
Sacré A; Lanthier N; Dano H; Aydin S; Leggenhager D; Weber A; Dekairelle AF; De Cuyper A; Gala JL; Humblet Y; Sempoux C; Van den Eynde M
Liver Int; 2016 Nov; 36(11):1590-1594. PubMed ID: 27500989
[TBL] [Abstract][Full Text] [Related]
31. Gastrointestinal perforation associated with bevacizumab in metastatic colorectal cancer.
Fang K; Wang J; Yuan J; Sui C; Zhi J; Xia Y; Sun M
Cancer Rep (Hoboken); 2024 Feb; 7(2):e1952. PubMed ID: 38258341
[TBL] [Abstract][Full Text] [Related]
32. Regorafenib as a single-agent in the treatment of patients with gastrointestinal tumors: an overview for pharmacists.
Rey JB; Launay-Vacher V; Tournigand C
Target Oncol; 2015 Jun; 10(2):199-213. PubMed ID: 25213039
[TBL] [Abstract][Full Text] [Related]
33. Regorafenib for cancer.
Strumberg D; Schultheis B
Expert Opin Investig Drugs; 2012 Jun; 21(6):879-89. PubMed ID: 22577890
[TBL] [Abstract][Full Text] [Related]
34. Gastrointestinal perforation related to lenvatinib, an anti-angiogenic inhibitor that targets multiple receptor tyrosine kinases, in a patient with metastatic thyroid cancer.
Date E; Okamoto K; Fumita S; Kaneda H
Invest New Drugs; 2018 Apr; 36(2):350-353. PubMed ID: 29018997
[TBL] [Abstract][Full Text] [Related]
35. Regorafenib antagonizes BCRP-mediated multidrug resistance in colon cancer.
Zhang YK; Wang YJ; Lei ZN; Zhang GN; Zhang XY; Wang DS; Al-Rihani SB; Shukla S; Ambudkar SV; Kaddoumi A; Shi Z; Chen ZS
Cancer Lett; 2019 Feb; 442():104-112. PubMed ID: 30392788
[TBL] [Abstract][Full Text] [Related]
36. Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603).
Fukuoka S; Hara H; Takahashi N; Kojima T; Kawazoe A; Asayama M; Yoshii T; Kotani D; Tamura H; Mikamoto Y; Hirano N; Wakabayashi M; Nomura S; Sato A; Kuwata T; Togashi Y; Nishikawa H; Shitara K
J Clin Oncol; 2020 Jun; 38(18):2053-2061. PubMed ID: 32343640
[TBL] [Abstract][Full Text] [Related]
37. Gastrointestinal perforation due to bevacizumab in colorectal cancer.
Saif MW; Elfiky A; Salem RR
Ann Surg Oncol; 2007 Jun; 14(6):1860-9. PubMed ID: 17356952
[TBL] [Abstract][Full Text] [Related]
38. Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial.
Mir O; Brodowicz T; Italiano A; Wallet J; Blay JY; Bertucci F; Chevreau C; Piperno-Neumann S; Bompas E; Salas S; Perrin C; Delcambre C; Liegl-Atzwanger B; Toulmonde M; Dumont S; Ray-Coquard I; Clisant S; Taieb S; Guillemet C; Rios M; Collard O; Bozec L; Cupissol D; Saada-Bouzid E; Lemaignan C; Eisterer W; Isambert N; Chaigneau L; Cesne AL; Penel N
Lancet Oncol; 2016 Dec; 17(12):1732-1742. PubMed ID: 27751846
[TBL] [Abstract][Full Text] [Related]
39. [Successful Administration of Regorafenib to a Metastatic Colon Cancer Patient with Impaired Performance Status by Reducing the Initial Dose].
Nishitai R; Manaka D; Kudo R; Mitsuoka E; Kanai S; Kanto S; Yoshino K; Hamasu SY; Konishi S; Yamashiro Y
Gan To Kagaku Ryoho; 2015 Jul; 42(7):871-3. PubMed ID: 26197753
[TBL] [Abstract][Full Text] [Related]
40. Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).
García-Alfonso P; Benavides M; Falcó E; Muñoz A; Gómez A; Sastre J; Rivera F; Montagut C; Salgado M; López-Ladrón A; López R; Ruiz de Mena I; Durán G; Aranda E;
Oncologist; 2018 Nov; 23(11):1271-e128. PubMed ID: 30120161
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
